Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 682

Sort by

Sort Order Select

Journal Articles

Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA

Blood (2020) 136 (1): 71–80.

https://doi.org/10.1182/blood.2019004460

Published: 2020

Includes: Supplemental data

Journal Articles

Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study

Vaishali Sanchorawala, Shayna Sarosiek, Amanda Schulman, Meredith Mistark, Mary Ellen Migre, Ramon Cruz, J. Mark Sloan, Dina Brauneis, Anthony C. Shelton

Blood (2020) 135 (18): 1541–1547.

https://doi.org/10.1182/blood.2019004436

Published: 2020

Journal Articles

A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis

Blood (2020) 135 (18): 1531–1540.

https://doi.org/10.1182/blood.2019004369

Published: 2020

Includes: Supplemental data

Journal Articles

Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria

Christoph R. Kimmich, Tobias Terzer, Axel Benner, Tobias Dittrich, Kaya Veelken, Alexander Carpinteiro, Timon Hansen, Hartmut Goldschmidt, Anja Seckinger, Dirk Hose, Anna Jauch, Stefan Wörner, Jörg Beimler, Carsten Müller-Tidow, Ute Hegenbart, Stefan O. Schönland

Blood (2020) 135 (18): 1517–1530.

https://doi.org/10.1182/blood.2019003633

Published: 2020

Includes: Supplemental data

Journal Articles

Sanchorawala V, Palladini G, Kukreti V, et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017;130(5):597-605.

Blood (2020) 135 (13): 1071.

https://doi.org/10.1182/blood.2020005086

Published: 2020

Journal Articles

Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis

Marco Basset, Irene Defrancesco, Paolo Milani, Mario Nuvolone, Sara Rattotti, Andrea Foli, Silvia Mangiacavalli, Marzia Varettoni, Pietro Benvenuti, Claudio Salvatore Cartia, Marco Paulli, Giampaolo Merlini, Luca Arcaini, Giovanni Palladini

Blood (2020) 135 (4): 293–296.

https://doi.org/10.1182/blood.2019002762

Published: 2020

Journal Articles

A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib

Richa Manwani, Oliver Cohen, Faye Sharpley, Shameem Mahmood, Sajitha Sachchithanantham, Darren Foard, Helen J. Lachmann, Cristina Quarta, Marianna Fontana, Julian D. Gillmore, Carol Whelan, Philip N. Hawkins, Ashutosh D. Wechalekar

Blood (2019) 134 (25): 2271–2280.

https://doi.org/10.1182/blood.2019000834

Published: 2019

Journal Articles

Clinical Characteristics, Treatment Regimens and Survival in Elderly Patients with AL Amyloidosis in a Tertiary Referral Center

Jose Acevedo, Gheorghe Doros, PhD, Raphael Szalat, John Mark Sloan, MD, Shayna Sarosiek, Vaishali Sanchorawala, MD

Blood (2019) 134 (Supplement_1): 5447.

https://doi.org/10.1182/blood-2019-124980

Published: 2019

Journal Articles

First Description of B Cell Maturation Antigen Expression in Light Chain Amyloidosis

Susan Bal, MDMBBS, Allison Sigler, Alexander Chan, MD, David J. Chung, MD PhD, Ahmet Dogan, MD PhD, Sergio A Giralt, MD, Hani Hassoun, MD, Heather J Landau, MD

Blood (2019) 134 (Supplement_1): 5452.

https://doi.org/10.1182/blood-2019-127332

Published: 2019

Journal Articles

Bortezomib Overcomes Poor Prognosis Conferred By High Sictp in Untreated Plasma Cell Disorders

Akira Honda, MD PhD, Yu Oyama, MD, Kazuhiro Toyama, MD PhD, Mineo Kurokawa, MD PhD

Blood (2019) 134 (Supplement_1): 5492.

https://doi.org/10.1182/blood-2019-129324

Published: 2019

Journal Articles

Amyloidosis and Plasma Cell Dyscrasias: A Single Institution Experience

Poornima Ramadas, MBBS, Ajay Tambe, MBBS, Mijung Lee, MD

Blood (2019) 134 (Supplement_1): 5463.

https://doi.org/10.1182/blood-2019-131577

Published: 2019

Journal Articles

Localized Pulmonary Amyloidosis: A Single Institution Experience

Ajay Tambe, MBBS, Poornima Ramadas, MBBS, Mijung Lee, MD, Kanish Mirchia, MD

Blood (2019) 134 (Supplement_1): 5464.

https://doi.org/10.1182/blood-2019-125124

Published: 2019

Journal Articles

Treatment of Non-Amyloid Monoclonal Gammopathies of Renal Significance (MGRS) with Clone Directed Therapies-Single Center Experience

Divaya Bhutani, MD, Vikram Premkumar, MD, Shayan Shirazayan, MD, Andrew Bomback, MD, Jai Radhakrishnan, MD, Suzanne Lentzsch, MD PhD

Blood (2019) 134 (Supplement_1): 5565.

https://doi.org/10.1182/blood-2019-128455

Published: 2019

Journal Articles

Real-World Data on Safety and Efficacy of Venetoclax-Based Regimens in Relapsed/Refractory t[11;14] Multiple Myeloma

Diana Basali, MD, Rajshekhar Chakraborty, MD, Lisa Rybicki, MS, Nathaniel Rosko, PharmD, Janice Reed, RN, Mary Ann Karam, RN, Kristen Schlueter, RN, Hayley Dysert, Beth M. Faiman, PhDCNP, Kimberly Hamilton, APRN/PA, Matt Kalaycio, MD, Jason Valent, MD

Blood (2019) 134 (Supplement_1): 5566.

https://doi.org/10.1182/blood-2019-129002

Published: 2019

Journal Articles

Histologic and Molecular Correlates in Patients with AL Amyloidosis in Remission but with Persistent Renal Disease

Cindy Varga, MD BSc, Viji Nair, PhD, Agnes Fogo, MD, Samih Nasr, MD, Bradley Godfrey, PhD, Felix Eichinge, PhD, Denis Toskic, BS, Matthias Kretzler, MD, Raymond L Comenzo, MD

Blood (2019) 134 (Supplement_1): 5500.

https://doi.org/10.1182/blood-2019-123228

Published: 2019

Journal Articles

Another Obesity Paradox: In Cardiac AL Amyloid a Higher BMI Is Associated with a Lower Rate of Cardiac Response

So Yeon Kim, MD, Amanda Vest, MD, Raymond L Comenzo, MD, Cindy Varga, MD BSc

Blood (2019) 134 (Supplement_1): 5502.

https://doi.org/10.1182/blood-2019-123890

Published: 2019

Journal Articles

A Real-Life Study of Autologous Stem-Cell Transplantation in Patients with Multiple Myeloma Older Than 65 Years in a Latin American Country

Cristian Maximiliano Seehaus, MD, Natalia Paola Schutz, MDMSc, Erika Barbara Brulc, MD, Leandro Burgos Pratx, MD, Gonzalo Ariel Ferini, MD, Jorge A Arbelbide, MD, Dorotea Fantl, MD, Ana Lisa Basquiera, MD PhD

Blood (2019) 134 (Supplement_1): 5711.

https://doi.org/10.1182/blood-2019-130171

Published: 2019

Journal Articles

A Comparison of the Effect of Granulocyte-Colony Stimulating Factor (G-CSF) in Chemotherapy Versus Plerixafor for Hematopoietic Stem Sell Transplantation (HSCT) and Mobilization

Flavia zattar Piazera, MD, Alexandre Nonino, MD, Rafael De Sá Vasconcelos, MD, Andre Luiz Soares Cunha, MD, Jorge Vaz Pinto, MD, Mariana Profiro, MD

Blood (2019) 134 (Supplement_1): 5712.

https://doi.org/10.1182/blood-2019-129523

Published: 2019

Journal Articles

Unequal Outcomes in Transplant Eligible Patients with Multiple Myeloma in Latin America: Differences between Public and Private Centers

Camila Peña, MD, Natalia Paola Schutz, MDMSc, Virginia Bove, MD, Fiorella Villano, MD, Rocío Osorio, MD, Mauricio Chandia, MD, Cecilia Beltran, MD, Javier Schulz, MD, Daniela Cardemil, MD, Carolina Contreras, MD, Carmen Gloria Vergara, MD, Javiera Donoso, MD, Marcela Espinoza, MD, Gabriel La Rocca, MD, Hernán López-Vidal, MD, Pilar León, MD, Christine Rojas, MD, Pablo Soto, MD, Sandra Aranda, MD, Vivianne Torres, MD, Paola Ochoa, MD, Patricio Duarte, MD, Guillermina Remaggi, MD, Sebastian Yantorno, MD, Ariel Corzo, MD, Soledad Zabaljauregui, MD, Claudia Shanley, MD, Sergio Lopresti, MD, Sergio Orlando, MD, Veronica Verri, MD, Luis Darío Quiroga, MD, Carlos García, MD, Vanesa Fernandez, MD, Dorotea Fantl, MD, Jhoanna Ramirez, MD, Alicia Molina, MD, Pilar Papilco, MD, Alex Mite, MD, Ines Reyes, MD, Brener Sabando, MD, Francisca M. Ramirez Aspiazu, MD, Claudia Lucia Sossa, MD, Virginia Abello, MD, Henry Idrobo, MD Professor, Kenny Galvez, MD, Domingo Saavedra, MD, Guillermo Quintero, MD MBA, Raimundo Gazitua, MD, Lina Gaviria, MD, Rigoberto Gomez, MD, Monica Osuna Pérez, MD, Alicia Henao-Uribe, MD, Luz del Carmen Tarín Arzaga, MD, Omar Cantú-Martínez, MD, David Gomez-Almaguer, MD, Yarely Itzayana García-Navarrete, MD, Antonio Cruz-Mora, MD, Yahveth Cantero-Fortiz, MD, Guillermo J. Ruiz-Arguelles, FRCP, MACP, Macarena Roa, MD, Eloisa Riva, MD

Blood (2019) 134 (Supplement_1): 5497.

https://doi.org/10.1182/blood-2019-127555

Published: 2019

Journal Articles

Profile of Long-Term Survivors in Multiple Myeloma

Blood (2019) 134 (Supplement_1): 5522.

https://doi.org/10.1182/blood-2019-127519

Published: 2019

NARROW

Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA

Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study

A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis

Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria

Sanchorawala V, Palladini G, Kukreti V, et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017;130(5):597-605.

Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis

A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib

Clinical Characteristics, Treatment Regimens and Survival in Elderly Patients with AL Amyloidosis in a Tertiary Referral Center

First Description of B Cell Maturation Antigen Expression in Light Chain Amyloidosis

Bortezomib Overcomes Poor Prognosis Conferred By High Sictp in Untreated Plasma Cell Disorders

Amyloidosis and Plasma Cell Dyscrasias: A Single Institution Experience

Localized Pulmonary Amyloidosis: A Single Institution Experience

Treatment of Non-Amyloid Monoclonal Gammopathies of Renal Significance (MGRS) with Clone Directed Therapies-Single Center Experience

Real-World Data on Safety and Efficacy of Venetoclax-Based Regimens in Relapsed/Refractory t[11;14] Multiple Myeloma

Histologic and Molecular Correlates in Patients with AL Amyloidosis in Remission but with Persistent Renal Disease

Another Obesity Paradox: In Cardiac AL Amyloid a Higher BMI Is Associated with a Lower Rate of Cardiac Response

A Real-Life Study of Autologous Stem-Cell Transplantation in Patients with Multiple Myeloma Older Than 65 Years in a Latin American Country

A Comparison of the Effect of Granulocyte-Colony Stimulating Factor (G-CSF) in Chemotherapy Versus Plerixafor for Hematopoietic Stem Sell Transplantation (HSCT) and Mobilization

Unequal Outcomes in Transplant Eligible Patients with Multiple Myeloma in Latin America: Differences between Public and Private Centers

Profile of Long-Term Survivors in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only